The first patient has been randomised in the TARGET BP I trial at the Piedmont Heart Institute in Atlanta, USA, to investigate the use of the Peregrine System Kit (Ablative Solutions) in renal denervation.
Target BP I is a blinded, randomised sham-controlled study that is evaluating the safety and efficacy of the system in the treatment of patients with uncontrolled hypertension who are taking two to five anti-hypertensive medications.
The company announced the trial’s commencement in a press release, which explains that the TARGET BP I trial and the ongoing European TARGET-BP OFF-MED trial are part of the TARGET BP clinical trials programme and are designed to evaluate the safety and efficacy of the Peregrine System Kit when used to treat patients with uncontrolled hypertension. The system is comprised of a patented infusion catheter and dehydrated alcohol.
David Kandzari (Piedmont Heart Institute, Atlanta, USA) co-principal investigator of the TARGET BP I trial, comments in the release: “It is exciting to initiate this important trial to evaluate the Peregrine System Kit for the treatment of patients with uncontrolled hypertension. More than half of those treated with anti-hypertensive medications do not achieve their target blood pressure, so there is a great need for improved therapeutic options.”